Index

Note: Page numbers of article titles are in boldface type.

A
Abuse, reporting of, 1229–1230
Acamprosate, for alcohol dependence, 1180
Acetylcholinesterase inhibitors, for dementia, 1111–1112
S-Adenosylmethionine (SAMe), 1155–1157
Adherence, to treatment, 1081–1082, 1206–1209, 1242
Advanced directives, 1233–1234
Agitation, in dementia, 1112
Agnosia, in Alzheimer disease, 1109
Alcohol use disorder, 1170–1180
  acute intoxication in, 1171–1172
  acute stages of, 1170
  dependence in, 1180
  epidemiology of, 1170
  late stages of, 1170–1171
  mechanism of action of, 1170–1171
  tolerance in, 1170–1171
Alcohol-Withdrawal Syndrome Scale, 1174
Alpha2-adrenergic receptor agonists, for alcohol withdrawal, 1177–1180
Alprazolam, 1148
  for anxiety disorders, 1133–1134
  intoxication with, 1184, 1187
  pharmacology of, 1186
Alzheimer disease, 1108–1109, 1111–1112
Amnesia, in Alzheimer disease, 1109
Amphetamines, abuse of, 1189
Anorexia, 1219
Anticholinergics
  abuse of, 1198
  delirium due to, 1107
  for forgetfulness, 1220
Anticonvulsants
  for alcohol withdrawal, 1176–1177
  for mood disorders, 1150–1152
Antidepressants, 1144–1147
  atypical, 1145–1146
  augmenting agents with, 1147
  for anxiety disorders, 1132–1133
  for dementia, 1112
  for insomnia, 1218
Antidepressants (continued)
for pain, 1217
for transplantation, 1243
for weight loss, 1219
mania or hypomania due to, 1124
natural remedies as, 1155–1157
practical approaches to, 1146–1147
sexual dysfunction due to, 1220–1221

Antihypertensives, for anxiety disorders, 1134
Antipsychotics, 1152–1155
for alcohol withdrawal, 1174–1176
for anxiety disorders, 1134
for dementia, 1112
for mood disorders, 1152
sexual dysfunction due to, 1221
typical, 1152–1154

Antisocial personality disorder, violence in, 1093

Anxiety disorders, 1127–1139
after ventricular assist device implantation, 1246
causes of, 1129–1132
classification of, 1128–1129
diagnosis of, 1128–1129
economic costs of, 1127
epidemiology of, 1127
evaluation of, 1129
in dementia, 1112
in transplant candidates, 1242–1243
pathophysiology of, 1128
posttransplant, 1244
prognosis for, 1136
screening for, 1129
treatment of, 1132–1136, 1146
antidepressants for, 1144
benzodiazepines for, 1147
collaborative, 1135–1136
counseling, 1134–1135
natural remedies for, 1157–1158
pharmacologic, 1132–1134
psychotherapy, 1134–1135

Anxiolytics, 1147–1149, 1157–1158, 1243
Apathy, 1118
Aphasia, in Alzheimer disease, 1109
Apology laws, 1234–1235
Appetite, loss of, 1219
Apraxia, in Alzheimer disease, 1109
Aripiprazole, 1153–1154
Asenapine, 1153–1154
Asthma, anxiety in, 1131–1132
Atenolol, for alcohol withdrawal, 1176
Attention deficits, in delirium, 1104
Attention-deficit/hyperactivity disorder, versus bipolar disorder, 1123
Baclofen
  for alcohol dependence, 1180
  for opioid withdrawal, 1185
Barbiturates, abuse of, 1194
Bedside behavior, 1164–1165
Behavioral therapy
  for anxiety disorders, 1134–1135
  for dementia, 1112–1113
Benzodiazepines, 1147–1148
  abuse of, 1184, 1186–1187, 1194, 1196–1197
  delirium due to, 1107
  dependence on, 1197
  for alcohol withdrawal, 1174
  for anxiety disorders, 1133–1134, 1243
  intoxication with, 1184, 1187, 1196
  pharmacology of, 1186
  withdrawal from, 1187, 1197
Bereavement care, 1248
Beta blockers
  for alcohol withdrawal, 1176
  for anxiety disorders, 1131, 1134
Bio-psycho-social-spiritual model, 1079–1080
Bipolar disorder, 1121–1124
  assessment of, 1122–1123
  differential diagnosis of, 1123–1124
  epidemiology of, 1117
  misconceptions about, 1121–1122
  suicide in, 1090
  treatment of, 1149–1152
  type I versus type II, 1124
Boundary violations, 1235
Buprenorphine, for opioid withdrawal, 1182, 1185
Bupropion, 1145–1146
  for fatigue, 1220
  for nicotine dependence, 1198
Burn injuries, reporting of, 1230
Buspirone, 1134, 1148–1149, 1243

C
Cachexia, 1219
Caffeine
  abuse of, 1188
  anxiety due to, 1131
Cannabinoids, abuse of, 1193
Capacity decisions, 1231–1232
Carbamazepine
  for alcohol withdrawal, 1176–1177
  for mood disorders, 1152
Catatonia, versus bipolar disorder, 1122–1123
Chest pain, in panic disorder, 1128
Child abuse, reporting of, 1229–1230
Chlordiazepoxide
  for anxiety disorders, 1133–1134
  for benzodiazepine withdrawal, 1197
  pharmacology of, 1186
Cholinergic neurons, oxidative stress on, delirium in, 1104–1105
Chronic illness
  mismatches in physician-patient relationship in, 1205–1214
  psychosocial treatment in, 1161–1167
  suicide in, 1090
Chronic obstructive pulmonary disease, anxiety in, 1131–1132
Cigarette smoking, 1197–1198
Citalopram, 1132–1133, 1144–1145
Clinical Institute Withdrawal Assessment for Alcohol-Revised, 1174
Clinical interviewing, in collaborative care, 1077–1078
Clomipramine, for anxiety disorders, 1133
Clonazepam, 1147–1148
  for anxiety disorders, 1133–1134
  pharmacology of, 1186
Clonidine
  for alcohol withdrawal, 1177–1178
  for opioid withdrawal, 1185
Clorazepate, pharmacology of, 1186
Clozapine, 1153–1155
Cocaine, abuse of, 1190
Cognitive behavioral therapy
  for alcohol dependence, 1180
  for anxiety disorders, 1134–1135
Cognitive impairment
  delirium. See Delirium.
  dementia, 1108–1113
  fatigue in, 1219–1220
Collaborative care, 1075–1088
  collaborative management model for, 1083–1084
  cultural competence and, 1077, 1080–1082
  discussion in, 1079–1080
  for anxiety disorders, 1135–1136
  history in, 1078–1079
  interviewing in, 1077–1078
  models for, 1083–1085
  preparation for, 1082–1083
  primary care-driven model for, 1084–1085
  specialty care in, 1082
  three-component model for, 1084
Command hallucinations, violence in, 1093–1094
Complementary and alternative medicine, 1155–1158
Confidentiality, 1227–1229
Confusion Assessment Mode, for delirium, 1106
Consciousness, disturbances of, in delirium, 1104
Consent, for treatment, 1231–1234
Consultation, collaborative care and, 1077
Conversion disorder, 1210, 1212
Coping
  definition of, 1162–1163
  enhancing mechanisms for, 1163
Cortical dementia, 1109
Corticosteroids, mania or hypomania due to, 1124
Counseling, for anxiety disorders, 1134–1135
Criminal behavior, injuries from, reporting of, 1230
Crisis, 1089–1102
  suicide in, 1089–1092
  violence in, 1092–1097
Cultural competence, collaborative care and, 1077, 1080–1082
Culture, definition of, 1080
Cyclosporine, neurotoxicity of, 1244

D
Death, fear of, 1130
Decisions, for treatment consent and refusal, 1231–1234
Delirium, 1103–1108
  after ventricular assist device implantation, 1246
  clinical presentation of, 1104
  diagnosis of, 1105–1106
  in alcohol withdrawal, 1179
  misdiagnosis of, 1104
  pathophysiology of, 1104–1105
  posttransplant, 1243–1244
  prevention of, 1107–1108
  timely identification of, 1104
  treatment of, 1106–1107
  versus bipolar disorder, 1122
  versus dementia, 1108
Delirium tremens, in alcohol withdrawal, 1173–1174
Delusions
  sick role overidentification in, 1211
  violence in, 1093–1094
Dementia, 1108–1113
  Alzheimer type, 1108–1109
  cortical, 1109
  definition of, 1108
  frontotemporal, 1123
  in Parkinson disease, 1111
  in psychiatric disorders, 1111
  reversible, 1111
  treatment of, 1111–1113
  types of, 1108–1111
  vascular, 1109–1110
  versus bipolar disorder, 1123
  versus delirium, 1108
  versus depression, 1118
Dementia (continued)
  versus pseudodementia, 1111
  with Lewy bodies, 1110–1111
Demographic factors, in violence, 1094
Demoralization, 1118
Denial, of illness, 1208
Dependence
  alcohol, 1180
  benzodiazepines, 1197
  nicotine, 1198
  opioid, 1183
Depressants, central nervous system, abuse of, 1194–1195
Depression
  after ventricular assist device implantation, 1246
  dementia in, 1111
  fatigue in, 1219–1220
  in transplant candidates, 1242–1243
  insomnia in, 1218
  major depressive disorder, 1117–1121, 1216
  posttransplant, 1244
  sexual dysfunction in, 1220–1221
  somatic symptoms in, 1216
  suicide in, 1090, 1092
  treatment of, 1092, 1144, 1146–1147, 1149–1152. See also Antidepressants.
    natural remedies for, 1155–1157
  weight loss in, 1219
Desipramine, for pain, 1217
Desvenlafaxine, 1144–1145
Developmental history, 1079
Dexmedetomidine, for alcohol withdrawal, 1179
Dextrose, for alcohol intoxication, 1171
Diabetes mellitus, failure to manage, 1206
Diarrhea
  in benzodiazepine withdrawal, 1197
  in opioid withdrawal, 1185
Diazepam, 1147–1148
  for alcohol withdrawal, 1177
  for anxiety disorders, 1133–1134
  intoxication with, 1184, 1187
  pharmacology of, 1186
DIG FAST mnemonic, for bipolar disorder, 1121
Diphenoxylate, for opioid withdrawal, 1185
Disinhibition, in dementia, 1112
Distraction, for anxiety disorders, 1135
Disulfuram, for alcohol dependence, 1180
Donepezil, for dementia, 1111–1112
Dopaminergic neurons, oxidative stress on, delirium in, 1104–1105
Draw-a-clock test, for delirium, 1105
Drugs
  abuse of. See Substance use and abuse.
  anxiety due to, 1131
delirium due to, 1107
mania or hypomania due to, 1124
neurotoxicity of, 1244
sexual dysfunction due to, 1220–1221
Duloxetine, 1144–1145, 1217
Duty to protect, 1228–1229
Dysphoria
   as normal state, 1118–1119
   assessment of, 1117
   differential diagnosis of, 1120
   in bipolar disorder, 1121
Dysthymia, treatment of, 1144

E
Eating disorders, 1219
Ecstasy (3,4-methylenedioxymethamphetamine), abuse of, 1189
Education, for collaboration, 1083
Elder abuse, reporting of, 1229–1230
Electroencephalography, for delirium, 1105–1106
End-of-life care, for transplant patients, 1246–1250
Erectile dysfunction, 1220–1221
Errors, medical, legal aspects of, 1234–1235
Escitalopram, 1132–1133, 1144–1145
Estazolam, pharmacology of, 1186
Eszopiclone, 1147–1149
   for insomnia, 1218
   pharmacology of, 1186
Ethanol abuse. See Alcohol use disorder.
Ethical codes, 1235

F
Factitious disorder, 1210–1212
Fatigue, 1219–1220
Fear, of death, 1130
Fluid therapy, for alcohol intoxication, 1171–1172
Flumazenil, for benzodiazepine intoxication, 1187, 1196
Fluoxetine, 1144–1145
Fluphenazine, 1152–1153, 1155
Flurazepam, pharmacology of, 1186
Fluvoxamine, for obsessive-compulsive disorder, 1133
Forgetfulness, 1219–1220
Four As (amnesia, apraxia, aphasia, agnosia), in Alzheimer disease, 1109
Four Ds, for malpractice claims, 1234
Frontotemporal dementia, 1123

G
Gabapentin, for alcohol dependence, 1180
GAD-7, for anxiety screening, 1129
Galantamine, for dementia, 1112
Gamma-aminobutyric acid sleep agents, 1147–1149, 1195
Generalized anxiety disorder
  prognosis for, 1136
  screening for, 1129
  sick role overidentification in, 1211
  treatment of, 1144, 1149
Genetic factors, in suicide, 1090
Ginkgo biloba, 1156–1157
Glutamate modulators, for dementia, 1111–1112
Guardian, for medical decisions, 1234
Gunshot wounds, reporting of, 1230

H
Hallucinations, violence in, 1093–1094
Hallucinogens, abuse of, 1191, 1198
Hallucinosis, in alcohol withdrawal, 1173
Haloperidol, 1152–1155
  for alcohol withdrawal, 1175
  for delirium, 1106–1107
Happiness, versus mania, 1121
Hare Psychopathy Checklist, 1095
Hashish, abuse of, 1193
Health Insurance Portability and Accountability Act, 1230–1231
Heart failure, ventricular assist devices for, 1245–1246
Heart transplantation, quality of life after, 1245
Herbal preparations, 1155–1158
Hippocratic Oath, confidentiality in, 1227–1228
Historical, Clinical, and Risk Management instrument, 1095
History taking, 1078–1079
HIV infections, psychiatric comorbidity with, 1208–1209
Hospice care, 1248–1249
Hypertension, resistance to treatment of, 1206–1207
Hyperthyroidism, anxiety in, 1131
Hypochondriasis, 1210
Hypomania, in bipolar disorder, 1121–1124

I
Iloperidone, 1153–1154
Immunosuppressants, neurotoxicity of, 1244
Inattention, in delirium, 1104
Infections
  mania or hypomania due to, 1124
  reporting obligations for, 1228
Informed consent, 1231–1233
Insomnia, 1147–1149, 1155–1158, 1218
Interviewing
  for alcohol dependence, 1180
  in collaborative care, 1077–1078

Index
Intoxication
   alcohol, 1171–1172
   benzodiazepines, 1184, 1187, 1196
   nicotine, 1198
   opiates, 1181–1182

K
Kava, 1156–1157

L
Lamotrigine
   for alcohol withdrawal, 1177
   for mood disorders, 1150–1151
Left ventricular assist devices, 1245–1246
Legal issues, 1227–1238
   advanced directives, 1233–1234
   capacity decisions, 1231–1232
   confidentiality, 1227–1229
   Health Insurance Portability and Accountability Act, 1230–1231
   malpractice, 1234–1235
   reporting obligations, 1227–1230
   surrogate decision making, 1233–1234
   treatment consent and refusal, 1231–1234
Lewy bodies, dementia with, 1110–1111
Liability, legal, 1234–1235
Lithium, 1149–1151
Litigation, for malpractice, 1234–1235
Liver transplantation, quality of life after, 1245
Loperamide, for opioid withdrawal, 1185
Lorazepam, 1147–1148
   for alcohol withdrawal, 1174
   for anxiety disorders, 1133–1134
   pharmacology of, 1186
LSD (lysergic acid diethylamide), abuse of, 1191
Lung transplantation, quality of life after, 1244–1245
Lysergic acid diethylamide, abuse of, 1191

M
MacArthur Initiative on Depression in Primary Care, 1084
Major depressive disorder, 1117–1121
   assessment of, 1118–1119
   diagnosis of, 1120–1121
   differential diagnosis of, 1117–1118, 1120
   epidemiology of, 1117
   secondary, 1120
   sick role overidentification in, 1211
   somatic symptoms in, 1216
   symptoms of, 1120–1121
Malingering, 1211
Malpractice, 1234–1235
Mania
in bipolar disorder, 1121–1124
in dementia, 1112
Marijuana, 1193
Massachusetts Male Aging Study, 1221
MDMA (3,4-methylenedioxyamphetamine), abuse of, 1189
Medical illness
adapting to, 1163–1165
anxiety about, 1130–1132
depression due to, 1120–1121
mismatches in physician-patient relationship in, 1205–1214
psychosocial treatment in, 1161–1167
suicide in, 1090
Melatonin, 1156–1157
Memantine, for dementia, 1112
Memory, natural remedies for, 1157
Mescaline, abuse of, 1192
Methadone, for opioid withdrawal, 1182, 1185
Methamphetamine, abuse of, 1189
3,4-Methylenedioxyamphetamine (MDMA), abuse of, 1189
Midazolam, pharmacology of, 1186
Mindfulness therapy, for anxiety disorders, 1135
Mini-Mental State Examination, for delirium, 1105
Mirtazapine, 1145–1146
for anxiety disorders, 1133
for weight loss, 1219
sexual dysfunction and, 1221
Monoamine oxidase inhibitors, 1133, 1146
Mood disorders, 1117–1126
Mood stabilizers, 1149–1152
MORPHINE-ABC mnemonic, for opioid effects, 1181
Motivation, lack of, 1118
Multi-infarct (vascular) dementia, 1109–1110
Munchausen syndrome, 1210–1211
Muscle spasms, treatment of, benzodiazepines for, 1147

N
Naloxone, for opioid intoxication, 1182
Naltrexone
for alcohol dependence, 1180
for opioid withdrawal, 1182
Narcissistic personality disorder, violence in, 1093
National Consensus Project for Quality Palliative Care guidelines, 1247
Natural remedies, 1155–1158
Neglect, reporting of, 1229–1230
Negligence, suits for, 1234–1235
Neurasthenia, 1219
Neuritic plaques, in Alzheimer disease, 1109
Neurofibrillary tangles, in Alzheimer disease, 1109
Neuroleptics, for delirium, 1106–1107
Nonadherence, to treatment, 1081–1082, 1206–1209, 1242

O

Obsessive-compulsive disorder
  diagnosis of, 1128–1129
  prognosis for, 1136
  treatment of, 1133, 1144
Olanzapine, 1153, 1155
  for alcohol withdrawal, 1175
  for delirium, 1106
Omega-3 fatty acids, 1155–1157
Ondansetron, for alcohol dependence, 1180
Opioids
  abuse of, 1181–1185
  delirium due to, 1107
  dependence on, 1183
  intoxication with, 1181–1182
  receptors for, 1181
  withdrawal from, 1182–1183, 1185
Oppression, 1118
Organ failure, transplantation for. See Transplantation.
Oxazepam, 1147–1148, 1186
Oxidative stress, delirium in, 1104–1105

P

Pain, psychiatric dimensions of, 1216–1217
Paliperidone, 1153, 1155
Palliative care, for transplant patients, 1246–1250
Palpitations, in panic disorder, 1128
Panic disorder
  asthma and, 1132
  diagnosis of, 1128
  prognosis for, 1136
  seizures in, 1132
  sick role overidentification in, 1211
  treatment of, 1144, 1147, 1149
Parkinson disease
  anxiety in, 1132
  dementia in, 1111
Paroxetine, 1144–1145
Patient Health Questionnaire-9, 1084
PCP (phencyclidine), abuse of, 1192
Perceptual deficits, in delirium, 1104
Perphenazine, 1152–1153
Persecutory delusions, violence in, 1093–1094
Personality disorders
  sick role overidentification in, 1211
Personality (continued)
  versus bipolar disorder, 1123
  violence in, 1093
Phencyclidine (PCP), abuse of, 1192
Phenytoin, for alcohol withdrawal, 1176
Poison Control Network, 1198–1199
Posttraumatic stress disorder
  diagnosis of, 1128
  posttransplant, 1244
  prognosis for, 1136
  treatment of, 1144
Prazeepam, pharmacology of, 1186
Prazosin, for anxiety disorders, 1134
Pregabalin, for alcohol dependence, 1180
Primary Care Evaluation of Mental Disorders, 1209
Primary care-driven model, for collaborative care, 1084–1085
Privacy issues, 1227–1229
Prognosis, anxiety about, 1130
Propranolol, for anxiety disorders, 1134
Pseudodementia, 1111
Psilocybin, abuse of, 1193
Psychiatric disorders
  anxiety. See Anxiety disorders.
  cognitive impairment, 1103–1116
  collaborative care for, 1075–1088
  crises in, 1089–1102
  in medical illness, 1161–1167, 1208–1209
  in transplantation candidates, 1239–1252
  legal issues in, 1227–1238
  mood disorders, 1117–1126
  multiple physical symptoms, 1205–1214
  pharmacotherapy for, 1141–1160
  somatic complaints, 1215–1225
  substance abuse in. See Substance use and abuse.
  suicide in, 1089–1092
  violent behavior in, 1092–1097
Psychiatrist, collaborative care with, 1075–1088
Psychodynamic psychotherapy
  for alcohol dependence, 1180
  for anxiety disorders, 1135
Psychopathy, violence in, 1093
Psychopharmacology, 1144–1160. See also specific agents and disorders.
  antidepressants, 1144–1147, 1155–1157
  antipsychotics, 1152–1155
  anxiolytics, 1147–1149, 1157–1158
  discontinuation of, 1143
  failure of, 1143
  goals of, 1142
  monitoring of, 1143
  mood stabilizers, 1149–1152
  natural remedies, 1155–1158
principles of, 1142–1143
selection of, 1142–1143
Psychosis
  anorexia in, 1219
  in dementia, 1112
  sick role overidentification in, 1211
  versus bipolar disorder, 1123
  violence in, 1093–1094
Psychosocial evaluation, pretransplant, 1240–1241
Psychosocial treatment, in medical illness, 1161–1167
Psychotherapy, for anxiety disorders, 1134–1135

Q
Quality of life
  transplantation and, 1244–1250
  with ventricular assist device, 1246
Quazepam, pharmacology of, 1186
Quetiapine, 1134, 1153–1154

R
Ramelteon, 1149
Reasonable patient standard, 1232
Recommendations, failure to adhere to, 1081–1082, 1206–1207
Referral, 1084–1085
Refusal, of treatment, 1231–1234
Relaxation, for anxiety disorders, 1134–1135
Reporting obligations, 1227–1230
Retransplantation, 1245
Reversible dementia, 1111
Risperidone, 1153–1155
  for anxiety disorders, 1134
  for delirium, 1107
Rivastigmine, for dementia, 1112
Rum fits, in alcohol withdrawal, 1173

S
S-adenosylmethionine (SAMe), 1155–1157
Safety issues, in suicide risk, 1091–1092
St. John’s wort, 1155–1157
SAMe (S-adenosylmethionine), 1155–1157
Schizoaffective disorder, 1123–1124
Schizophrenia
  sick role overidentification in, 1211
  treatment of, 1153–1155
  versus bipolar disorder, 1123
  violence in, 1094
Seizures
  in alcohol withdrawal, 1173
  in panic disorder, 1132
Selective serotonin uptake inhibitors, 1144, 1146–1147
   for anxiety disorders, 1132–1133
   for dementia, 1112
Selegiline, 1133, 1146
Sequenced Trial to Relieve Depression, 1221
Serotonin norepinephrine reuptake inhibitors, 1144–1146
   for anxiety disorders, 1132–1133
   for pain, 1217
Sertraline, 1132–1133, 1144–1145
Sexual assault, reporting of, 1230
Sexual dysfunction, 1220–1221
Shakes, in alcohol withdrawal, 1172–1173
Sick role
   failure to adopt, 1206
   overidentification of, 1209–1212
SIG: E CAPS mnemonic, for major depressive disorder, 1119
Sildenafil, for erectile dysfunction, 1221
Sirolimus, neurotoxicity of, 1244
Sleep agents, 1147–1149, 1157–1158, 1218
Sleep disturbance, in dementia, 1112
Smoking, nicotine use in, 1197–1198
Social anxiety disorder, diagnosis of, 1128
Social factors, in violence, 1094
Social history, 1079
Somatic disorders, 1124, 1209–1212
Somatic symptoms, 1215–1225
   anorexia, 1219
   depression and, 1216
   fatigue, 1219–1220
   forgetfulness, 1219–1220
   insomnia, 1218
   medically unexplained, 1222
   pain, 1216–1217
   sexual dysfunction, 1220–1221
   treatment of, nonresponse to, 1221–1222
   weight loss, 1219
Somatization disorder, 1210
Somatoform disorders, 1210
Spiritual concerns, in medical illness, 1164
Stimulants, abuse of, 1188–1190, 1198
Strangers, anxiety about, 1130
Stress, violence in, 1094
Stroke, anxiety after, 1132
Substance use and abuse, 1169–1204
   alcohol, 1170–1180
   anxiety in, 1131
   benzodiazepines, 1184, 1186–1187, 1196–1197
   cannabinoids, 1193
   depressants, 1194–1195
   depression due to, 1120
   epidemiology of, 1169
hallucinogens, 1191–1193
nicotine, 1197–1198
opioids, 1181–1185
stimulants, 1188–1190
transplantation in, 1241–1242
violence in, 1093
Suicide and suicide risk, 1089–1092
clinical presentation, 1091
epidemiology of, 1090
evaluation of, 1091
methods for, 1090
risk factors for, 1090
treatment of, 1091–1092
Surrogate decision making, 1233–1234

T
Tacrolimus, neurotoxicity of, 1244
Temazepam, pharmacology of, 1186
Tetrahydrocannabinol, abuse of, 1193
Threat/control/override symptoms, violence in, 1093–1094
Three Component Model, for collaborative care, 1084
Tobacco use, 1197–1198
Tolerance, to alcohol, 1170–1171
Topiramate
   for alcohol dependence, 1180
   for alcohol withdrawal, 1177
Transplantation, psychiatric issues in, 1239–1252
   anxiety, 1243
   comorbid psychiatric disorders, 1242–1243
   depression, 1243
   immunosuppressant neurotoxicity, 1244
   nonadherence risks, 1242
   palliative care, 1246–1250
   posttransplant, 1243–1245
   pretransplant, 1240–1241, 1243
   quality of life, 1244–1245
   retransplantation, 1245
   substance abuse, 1241–1242
   ventricular assist device implantation for, 1245–1246
Trazodone, 1148–1149
Treatment consent and refusal, 1231–1234
Tremors, in alcohol withdrawal, 1172–1173
Trazolam, pharmacology of, 1186
Tricyclic antidepressants, 1133, 1146

V
Valproic acid, for mood disorders, 1150–1152
Varenicline, for nicotine dependence, 1198
Vascular dementia, 1109–1110
Venlafaxine, 1144–1145
Ventricular assist devices, 1245–1246
Violence, 1092–1097
  clinical variables in, 1094–1095
  mental illness and, 1092–1094
  risk assessment of, 1095–1097
  socioeconomic factors in, 1094
Violence Risk Appraisal Guide, 1095
Vitamin deficiencies, dementia in, 1111

W
Weight loss, 1219
Wernicke encephalopathy, 1171
WHHHHIMPS mnemonic, for delirium, 1104–1105
Withdrawal
  from alcohol use, 1172–1180
    delirium tremens in, 1173–1174
    early, 1172–1173
    hallucinosis in, 1173
    seizures in, 1173
    treatment of, 1174–1180
  from benzodiazepines, 1187, 1197
  from nicotine, 1198
  from opioids, 1182–1183, 1185
Worry, in anxiety disorders, 1128

Z
Zaleplon, 1147–1149, 1186
Ziprasidone, 1107, 1153–1154
Zolpidem, 1147–1149
  for insomnia, 1218
  pharmacology of, 1186